Month: March 2026

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) — Marex Group plc (‘Marex’, NASDAQ: MRX), the diversified global financial services platform, provides details for its upcoming Investor Day being held at the Nasdaq MarketSite in New York on March 26, 2026. The event will feature presentations from Ian Lowitt, CEO, Rob Irvin, CFO, and other senior leadership.What:  Marex Group plc Investor Day 2026When: Thursday, March 26, 2026  9:00am – 12:30pm ESTWhere:  Nasdaq MarketSite, New York   A light breakfast will be held from 8:30am and the event will be followed by an informal lunch. The event will take place at Nasdaq MarketSite in New York, and a live stream of the event will be available via webcast. Interested parties can access the webcast here, or through the ‘News & Events’ section of the Marex investor website...

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) — Nuvini Group Limited (Nasdaq: NVNI) (“Nuvini” or the “Company”), a leading acquirer and operator of profitable B2B software businesses across Latin America and emerging markets, today announced that it has reached an agreement with the founders of its previously acquired portfolio companies to extend to April 30, 2026 the deadline to pay the earnout obligations due to such founders at the negotiated discounted amount. The extension reflects the Company’s continued commitment to a collaborative and disciplined approach to balance sheet optimization, and its ongoing efforts to strengthen its capital structure in support of its acquisition strategy, as well as the founders’ belief in the Company’s long-term value. About NuviniHeadquartered in São Paulo, Brazil, Nuvini is Latin America’s leading...

New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21 Preclinical data highlight combination potential for ZW191, a folate receptor alpha (FR⍺)-targeting antibody-drug conjugate (ADC) New ADC candidates, including ZW437 and ZW418, demonstrate strong activity across RAS-mutated cancers based on a novel pan-RAS inhibitor ADC platformVANCOUVER, British Columbia , March 17, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the acceptance of an oral presentation and six abstracts from its wholly-owned R&D portfolio for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting,...

TORONTO, March 17, 2026 (GLOBE NEWSWIRE) — As part of its ongoing commitment to regularly review its product lineup, AGF Investments Inc. (AGF Investments) (TSX:AGF.B) today announced a series of changes to further streamline its product suite, including pricing reductions, fund terminations and a fund merger. These changes support AGF Investments’ goal of ensuring clients have access to products that remain relevant, competitive and aligned with evolving market trends. Pricing Reductions AGF Investments is reducing management fees and administration fees on the following funds/series effective April 1, 2026: Management Fee ReductionsFund Series Current Management Fee (in %) Updated Management Fee (in %)AGF Canadian Money Market Fund MF 1.00 0.90AGF Global Growth Balanced Fund MF/T/V 2.00 1.80Administration Fee Reductions...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that multiple abstracts highlighting the potential of rinzimetostat (ORIC-944), a potent and selective allosteric inhibitor of PRC2 to treat prostate cancer, have been accepted for poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22, 2026 in San Diego, CA. All regular abstracts are available for viewing via AACR’s online itinerary planner located here. Poster presentations details:Date & Time: Wednesday, April 22, 2026, 9:00 a.m. – 12:00 p.m. PTSession Category: Experimental and Molecular TherapeuticsSession...

Fireside chat to be webcast live during the symposium WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE) — William C. Whitaker, senior vice president and chief financial officer, Ashland (NYSE: ASH), will participate in a fireside chat at the Gabelli Funds’ 17th Annual Specialty Chemicals Symposium on Thursday, March 19, 2026, at 1:30 p.m. ET.  Whitaker will also host one‑on‑one meetings with institutional investors throughout the day. The symposium will feature discussions with leading companies and organizations across the specialty chemicals ecosystem, with an emphasis on industry dynamics, current trends, business fundamentals, and specialty chemicals investing. Investment professionals and individual investors interested in the specialty chemicals sector can register to listen to the live webcast at: https://gabelli.com/event/17th-annual-chemical-conference/ About Ashland Ashland...

Company Has Demonstrated Momentum on Transformation Strategy with Significant Regulatory and Commercial Milestones Approaching in 2026 Highlights Extensive Engagement with Altai Altai Has Rejected All Settlement Proposals and Is Singularly Focused on Securing Board Representation for Its Founder to Force an Ill-Timed Sale Process BETHLEHEM, Pa., March 17, 2026 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (“OraSure” and the “Company”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today issued the following statement in response to Altai Capital’s March 17, 2026, letter: OraSure’s Board and management team are steadfast in our commitment to driving value and acting in the best interests of all shareholders through disciplined execution and rigorous oversight. Rishi Bajaj, Altai’s...